Crothers Barbara A, Moriarty Ann T, Fatheree Lisa A, Booth Christine N, Tench William D, Wilbur David C
Department of Pathology and Laboratory Services, Walter Reed Army Medical Center, Washington, DC 20307-5001, USA.
Arch Pathol Lab Med. 2009 Jan;133(1):44-8. doi: 10.5858/133.1.44.
In 2006, 9643 participants took the initial College of American Pathologists (CAP) Proficiency Test (PT). Failing participants may appeal results on specific test slides. Appeals are granted if 3 referee pathologists do not unanimously agree on the initial reference diagnosis in a masked review process.
To investigate causes of PT failures, subsequent appeals, and appeal successes in 2006.
Appeals were examined, including patient demographic information, Centers for Medicare and Medicaid Services category (A, B, C, or D), exact reference diagnosis, examinees per appeal, examinee's Centers for Medicare and Medicaid Services category, referee's Centers for Medicare and Medicaid Services category, slide preparation type, and slide field validation rate.
There was a 94% passing rate for 2006. One hundred fifty-five examinees (1.6%) appealed 86 slides of all preparation types. Forty-five appeals (29%) were granted on 21 slides; 110 appeals (72%) were denied on 65 slides. Reference category D and B slides were most often appealed. The highest percentage of granted appeals occurred in category D (35% slides; 42% of participants) and the lowest occurred in category B (9% slides; 8% of participants). The field validation rate of all appealed slides was greater than 90%.
Despite rigorous field validation of slides, 6% of participants failed. Thirty percent of failing participants appealed; most appeals involved misinterpretation of category D as category B. Referees were never unanimous in their agreement with the participant. The participants and referees struggled with the reliability and reproducibility of finding rare cells, "overdiagnosis" of benign changes, and assigning the morphologically dynamic biologic changes of squamous intraepithelial lesions to static categories.
2006年,9643名参与者参加了美国病理学家学会(CAP)的初始能力验证测试(PT)。未通过的参与者可就特定测试玻片的结果提出申诉。如果3名裁判病理学家在盲法评审过程中对初始参考诊断未达成一致意见,则申诉会被批准。
调查2006年PT未通过、后续申诉及申诉成功的原因。
对申诉进行审查,包括患者人口统计学信息、医疗保险和医疗补助服务中心类别(A、B、C或D)、确切的参考诊断、每次申诉的应试者、应试者的医疗保险和医疗补助服务中心类别、裁判的医疗保险和医疗补助服务中心类别、玻片制备类型以及玻片视野验证率。
2006年的通过率为94%。155名应试者(1.6%)就所有制备类型的86张玻片提出申诉。45项申诉(29%)涉及21张玻片并获批准;110项申诉(72%)涉及65张玻片并被驳回。参考类别D和B的玻片最常被申诉。获批申诉的最高比例出现在类别D(35%的玻片;42%的参与者),最低比例出现在类别B(9%的玻片;8%的参与者)。所有申诉玻片的视野验证率均高于90%。
尽管对玻片进行了严格的视野验证,但仍有6%的参与者未通过。30%未通过的参与者提出了申诉;大多数申诉涉及将类别D误判为类别B。裁判们从未与参与者达成一致意见。参与者和裁判在发现罕见细胞的可靠性和可重复性、良性改变的“过度诊断”以及将鳞状上皮内病变形态学动态生物学改变归为静态类别方面存在困难。